Clinical trials: Conjunctivitis
Allergic Conjunctivitis
Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment
The present study will be carried out to evaluate the antiallergic efficacy of Bepotastine besilate 1.5% free of preservatives versus standard treatment with 0.2% Olopatadine hydrochloride with 0.1% benzalkonium chloride as…
- Trial name
- NCT04776096
- Testing
- Bepotastine Besilate 1.5% PF, Olopatadine Hydrochloride 0.2% BAK
- Where
- 4 sites in Argentina
- Volunteers
- 97 people
- Sponsor
- Laboratorios Poen
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "Hyaluronic Acid (HA)-Based Eyedrops" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a common ocular condition characterized by a loss of homeostasis of the tear film and inflammation of the ocular surface.
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05807360
- Testing
- Hyaluronic acid eye drops
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Allergic Conjunctivitis
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered…
- Trial name
- NCT06686472
- Testing
- TL-925
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Telios Pharma, Inc.
Keratoconjunctivitis Sicca
Effect of Controlled Adverse Environment (CAE) on Tear Film Stability
The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.
- Trial name
- NCT01547936
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ORA, Inc.
Dry Eye Syndrome, Keratoconjunctivitis Sicca
A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.
- Trial name
- NCT02680158
- Testing
- Oculeve Intranasal, Oculeve Extranasal
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oculeve, Inc.
Bacterial Conjunctivitis
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (TID) for seven days…
- Trial name
- NCT01330355
- Testing
- Besivance, Gatifloxacin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca
A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02139033
- Testing
- Retaine™
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Ocusoft, Inc.
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Acute Adenoviral Conjunctivitis
FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.
- Trial name
- NCT01470664
- Testing
- FST-100, FST-100 (Component #1), FST-100 Vehicle
- Where
- 2 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- Shire
Conjunctivitis, Conjunctivitis, Bacterial
Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects
Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V.
- Trial name
- PRO-174/I (NCT03519516)
- Testing
- PRO-174, Sophixín Ofteno®
- Where
- Mexico
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Rhino-Conjunctivitis, Urticaria
To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions
An open label, balanced, randomized single-dose, two-treatment, two sequence, four-period, Full Replicate, crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
- Trial name
- NCT07042828
- Testing
- Bilastine oral dispersible tablets, Bilaxten oral dispersible tablets
- Where
- India
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Conjunctivitis, Allergic
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a…
- Trial name
- NCT01289431
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation, Keratoconjunctivitis
Tolerability Comparison of Flarex to Lotemax SM
This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects.
- Conditions
- Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications
- Trial name
- NCT07588074
- Testing
- Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Harrow Inc